London · Delayed Price · Currency is GBP · Price in GBX Georgia Capital Earnings Call Transcripts
Fiscal Year 2026
-
NAV per share grew over 9% year-to-date, driven by strong portfolio company performance and robust Georgian macroeconomic conditions. Retail Pharmacy, Healthcare, and Insurance segments all delivered double-digit revenue and EBITDA growth, while capital return and buyback programs continued.
Fiscal Year 2025
-
EV per share rose 14.1% in Q4 and 61% for the year, driven by strong portfolio and macroeconomic performance. Capital return program is ahead of schedule, with 80% completed, and key segments—retail pharmacy, insurance, and healthcare—delivered double-digit growth and robust cash flow.
-
NAV per share rose nearly 8% in Q3, driven by strong operating results and share buybacks. Retail pharmacy, insurance, and healthcare segments all posted double-digit growth, with record profitability and robust cash flow. Capital return and dividend programs are ahead of schedule.
-
NAV per share rose 17.7% in Q2, driven by strong revenue and EBITDA growth across all major segments. GEL 300 million buyback completed early; new GEL 700 million capital return program launched. Insurance achieved investment-grade rating, and all segments reported robust cash generation.
-
NAV per share rose 11.2% in Q1, driven by strong revenue and EBITDA growth in private portfolio companies. Aggressive buybacks continued, with over 27% of shares repurchased, and dividend income per share increased 11.6%. Georgia's macro environment remains robust, supporting further growth.
Fiscal Year 2024
-
Record NAV and EBITDA growth were achieved, driven by strong portfolio company performance, major divestments, and significant share buybacks. Leverage declined, free cash flow surged, and the outlook remains positive with continued capital returns and robust macroeconomic conditions.
-
NAV per share rose 6.2% in Q3, driven by strong portfolio company performance, record dividend inflows, and a major beer business sale at a 40% premium to NAV. Operating cash flow and EBITDA reached record highs, while buybacks reduced share count near demerger levels.
-
NAV declined 12.8% in Q2 due to higher cost of equity and market volatility, despite strong EBITDA and revenue growth across portfolio companies. Buyback program expanded, with robust liquidity and positive macroeconomic outlook, though political risks remain.